velopment programs and other cash expenditures, our
history of operating losses and accumulated deficits, risks and uncertainties
related to our ability to raise cash under difficult capital market
conditions, our reliance on collaborative relationships and critical
personnel, and current and future competition, as well as other risks
described from time to time in filings we make with the Securities and
Exchange Commission. We undertake no obligation to release publicly the
results of any revisions to these forward-looking statements to reflect events
or circumstances arising after the date hereof.
Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.
For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com.
Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium
Therapeutics, Inc.
Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM) are
trademarks of Tissue Repair Company.
InnerCool Therapies(R), InnerCool(R), Celsius Control System(R),
RapidBlue(TM), CoolBlue(TM), Accutrol(R), Temperature Control Element(R),
TCE(R) and UroCool(TM) are trademarks of InnerCool Therapies, Inc.
'/>"/>SOURCE Cardium Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine news :1.
Cardium Completes $6.0 Million Financing2.
Cardium Announces InnerCools Endovascular Cooling to be Featured on Science Channels Series Cool Stuff: How It Works3.
Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems4.
Cardium Reports on Recent Highlights and Financial Results5.
An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells6.
AANMA Announces Launch of Free Web-Based Education Program for Patients Transitioning From CFC to HFA Inhalers7.
Lucas Group Announces Their Executive Recruitment Military Hiring Conference Schedule for December 2008 8.
Axiom Consulting Partners Announces the Results of its Return On Sales Investment Survey9.
United American Healthcare Corporation Announces Stock Repurchase Program10.
eOn Communications Announces GSA Contract11.
Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints